Clinical Trials Directory

Trials / Completed

CompletedNCT00056550

Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.

A Study to Assess the Incidence of Deep Vein Thrombosis (DVT) Following Prophylactic Intravenous Administration of Recombinant Human Antithrombin(rhAT) to Hereditary Antithrombin (AT) Deficient Patients in High Risk Situations.

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
14 (actual)
Sponsor
rEVO Biologics · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Patients with hereditary antithrombin (AT) deficiency are at increased risk of venous thrombosis and pulmonary embolism, particularly during certain high risk procedures. The trial is focusing on patients with confirmed hereditary antithrombin deficiency who are undergoing a surgical procedure or induced/spontaneous labor and delivery. The study will test the safety and efficacy of recombinant human antithrombin (rhAT) by infusing rhAT prior to, during and following the period of risk or surgical procedure.

Detailed description

Objectives : 1. Assess the safety of recombinant antithrombin (rhAT) in hereditary antithrombin (AT) deficient patients. 2. Assess the incidence of acute deep venous thrombosis(DVT) alone in patients with hereditary antithrombin (AT) deficiency in situations usually associated with a high risk for thromboembolic events after increasing and targeting functional AT activity at \>80% and \< 120% of normal by prophylactic IV administration of rhAT. 3. Clinically assess and determine the relevance of thromboembolic events other than acute DVT to rhAT administration.

Conditions

Interventions

TypeNameDescription
BIOLOGICALRecombinant Human Antithrombin (rhAT)Biological/Vaccine: Recombinant human antithrombin(rhAT) Phase III clinical trial.

Timeline

Start date
2002-12-01
Primary completion
2004-02-01
Completion
2004-02-01
First posted
2003-03-18
Last updated
2012-10-16
Results posted
2012-10-16

Locations

11 sites across 6 countries: United States, France, Germany, Italy, Sweden, United Kingdom

Source: ClinicalTrials.gov record NCT00056550. Inclusion in this directory is not an endorsement.